Introduction

Although traditional morphology has played a secondary role to the rapid developments in molecular biology, cytogenetics, and new areas of therapy for patients with multiple myeloma, its importance cannot be underestimated. Furthermore, new cytogenetic and molecular data, which relate morphologic appearances to chromosomal translocations (i.e., the association of CD20 expression, t(11;14) translocations, and small mature plasma cell morphology),1 have the potential to play considerable therapeutic roles in decision making about appropriate treatment for patients with myeloma.

0 0

Post a comment